Egil Støre Blix
Endre Gabrielsen,
Anna Maria Wirsing,
Tom Wilsgaard,
Inger Thune,
Hanne Frydenberg,
Trygve Lofterød
m.fl.:
Parity, breastfeeding, and reproductive timing are associated with tumour-infiltrating lymphocytes in hormone receptor-negative breast cancer: a population-based cohort study
ESMO Open 18. september 2026 DOI
Kathrine Flørenes Vandraas,
Sarah Hjorth Andersen,
Cassia Bree Trewin-Nybråten,
Bettina Kulle Andreassen,
Egil Støre Blix,
Bjørn Naume
m.fl.:
Translating CLEOPATRA into routine practice: National treatment patterns and survival for patients with HER2-positive metastatic breast cancer
Birgitte V. Offersen,
Jan Alsner,
Kristine Høgsbjerg,
Hanne M. Nielsen,
Else Maae,
Mette H. Nielsen
m.fl.:
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
Kristine Wiborg Høgsbjerg,
Mette Skovhus Thomsen,
Else Maae,
Ingvil Mjaaland,
Mette Holck Nielsen,
Maja Vestmø Maraldo
m.fl.:
Validation of the ESTRO target volume consensus guideline for early-stage breast cancer in the DBCG Skagen Trial 1
Kathinka Schmidt Slørdahl,
Katarina Puco,
Ragnhild Sørum Falk,
Ingrid Dyvik,
Sigmund Brabrand,
Pitt Niehusmann
m.fl.:
Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial
Christina Engebrethsen,
Synnøve Yndestad,
Mari Eskild Rasmussen,
Emiel Janssen,
Bjørnar Gilje,
Egil Støre Blix
m.fl.:
Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: An open-label, phase II study
Endre Gabrielsen,
Tom Wilsgaard,
Hanne Frydenberg,
Trygve Lofterød,
Stig Manfred Dalen,
Elin Synnøve Mortensen
m.fl.:
Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study
Kathrine Flørenes Vandraas,
Sarah Hjorth Andersen,
Cassia Bree Trewin-Nybråten,
Giske Ursin,
Edoardo Botteri,
Bettina Kulle
m.fl.:
Anti‐Her2 therapy patterns in metastatic breast cancer—Real‐world data suggest undertreatment
Torbjørn Omland,
Siri Lagethon Heck,
Espen Holte,
Albulena Mecinaj,
Mari Nordbø Gynnild,
Morten Fagerland
m.fl.:
Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial
Lars Asphaug,
Lars Andreas Akslen,
Egil Støre Blix,
Beate Boge,
Elin Faye Borgen,
Marianne B. Brekke
m.fl.:
Cost-Effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives
Dagny Førde,
Thomas Karsten Kilvær,
Mona Irene Pedersen,
Egil Støre Blix,
Ilona Halva Urbarova,
Erna-Elise Paulsen
m.fl.:
High density of TCF1+ stem-like tumor-infiltrating lymphocytes is associated with favorable disease-specific survival in NSCLC
Hege Oma Ohnstad,
Egil Støre Blix,
Lars Andreas Akslen,
Bjørnar Gilje,
Sunil Xavier Raj,
Helle Skjerven
m.fl.:
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1)
Katarina Puco,
Gro Live Fagereng,
Sigmund Brabrand,
Pitt Niehusmann,
Egil Støre Blix,
Eli Sihn Samdal Steinskog
m.fl.:
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
Jürgen Geisler,
Peeter Karihtala,
Malgorzata Tuxen,
Antonis Valachis,
Cecilia Ahlin,
Cathrine Bergquist Fosskaug
m.fl.:
Current treatment landscape of HR+/HER2− advanced breast cancer in the Nordics: a modified Delphi study
Oleksii Nikolaienko,
Hans Petter Eikesdal,
Elisabet Ognedal Berge,
Bjørnar Gilje,
Steinar Lundgren,
Egil Støre Blix
m.fl.:
Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
Synnøve Yndestad,
Christina Engebrethsen,
A. Herencia-Ropero,
Oleksii Nikolaienko,
Olav Karsten Vintermyr,
Reidun Kristine Lillestøl
m.fl.:
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer
Albulena Mecinaj,
Geeta Gulati,
Siri Lagethon Heck,
Espen Holte,
Morten Wang Fagerland,
Alf Inge Larsen
m.fl.:
Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial
Thomas Helland,
Bjørn Naume,
Steinar Hustad,
Ersilia Bifulco,
Jan Terje Kvaløy,
Anna Barbro Sætersdal
m.fl.:
Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
Hans Petter Eikesdal,
Synnøve Yndestad,
Asmaa Elzawahry,
Alba Llop-Guevara,
Bjørnar Gilje,
Egil Støre Blix
m.fl.:
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Lars Ottestad,
Line Fronth,
Sajitha Rajendiran,
Liv Hege Aksnes,
Hans Petter Eikesdal,
Egil Støre Blix
m.fl.:
Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
Sigurd Hald,
Mehrdad Rakaee,
Inigo Zubiavrre Martinez,
Elin Richardsen,
Samer Al-Saad,
Erna Elise Paulsen
m.fl.:
LAG-3 in Non-Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival
Giulio Francolini,
Mette S. Thomsen,
Esben S. Yates,
Carine Kirkove,
Ingelise Jensen,
Egil Støre Blix
m.fl.:
Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1
Ahmed R. Eldesoky,
Giulio Francolini,
Mette S. Thomsen,
Esben S. Yates,
Tine B. Nyeng,
Carine Kirkove
m.fl.:
Dosimetric assessment of an Atlas based automated segmentation for loco-regional radiation therapy of early breast cancer in the Skagen Trial 1: A multi-institutional study
AR Eldesoky,
ES Yates,
TB Nyeng,
MS Thomsen,
HM Nielsen,
P Poortmans
m.fl.:
Internal and external validation of an ESTRO delineation guideline - dependent automated segmentation tool for loco-regional radiation therapy of early breast cancer.
Kari Flo,
Egil Støre Blix,
Anne Husebekk,
Anders Thommassen,
Andreas Tendeland Uhre,
Tom Wilsgaard
m.fl.:
A longitudinal study of maternal endothelial function, inflammatory response and uterine artery blood flow during the second half of pregnancy
Egil Støre Blix,
Anne Husebekk
:
Raiders of the lost mark – endothelial cells and their role in transplantation for hematologic malignancies
Egil Støre Blix,
Anders Benjamin Kildal,
Eirin Listau Bertelsen,
Anders Waage,
June Myklebust,
Arne Kolstad
m.fl.:
Content of endothelial progenitor cells in autologous stem cellgrafts predict survival after transplantation for multiplemyeloma
Turid Rygh Skaara,
Katarina Puco,
Ingrid Dyvik,
Kathinka Schmidt Slørdahl,
Ragnhild Sørum Falk,
Sigmund Brabrand
m.fl.:
Alteration-matched therapy in advanced lung cancer: results from the IMPRESS-Norway study
15. september 2026 ARKIV
Victoria Vinje-Jakobsen,
Mari Nordbø Gynnild,
Albulena Mecinaj,
Torbjørn Wisløff,
Espen Holte,
Torgeir Wethal
m.fl.:
The effect of sacubitril/valsartan on functional disability and skeletal muscle injury during breast cancer therapy: insights from the PRADA II trial
29. august 2026 ARKIV
Mari Nordbø Gynnild,
Geeta Gulati,
Albulena Mecinaj,
Torgeir Wethal,
Espen Holte,
Victoria Vinje-Jakobsen
m.fl.:
Baseline and early changes in cardiac biomarkers as predictors of global longitudinal strain deterioration during breast cancer therapy: a PRADAII substudy
19. juni 2026 ARKIV
Mari Nordbø Gynnild,
Geeta Gulati,
Albulena Mecinaj,
Torgeir Wethal,
Espen Holte,
Victoria Vinje-Jakobsen
m.fl.:
Baseline and early changes in cardiac biomarkers as predictors of global longitudinal strain deterioration during breast cancer therapy: a PRADAII substudy
Masoud Tafavvoghi,
Falah Jabar Rahim,
Marte Berglund,
Amin Nassar,
Egil Støre Blix,
Elin Synnøve Mortensen
m.fl.:
Benchmarking histology foundation models to identify Prosigna high-risk breast cancer patients.
Katarina Puco,
Eli Sihn Samdal Steinskog,
Egil Støre Blix,
Sigmund Brabrand,
Åsmund Flobak,
Åse Haug
m.fl.:
Clinical benefit of genomic-guided targeted therapies in patients with rare cancers: First results from the IMPRESS-Norway trial
Sigmund Brabrand,
Eli Sihn Samdal Steinskog,
Egil Støre Blix,
Åsmund Flobak,
Katarina Puco,
Gro Live Fagereng
m.fl.:
3137O IMPRESS-Norway: A nationwide precision-oncology study for off-label targeted therapies - Results from the first 1,740 patients
Åslaug Helland,
Kjetil Tasken,
Kristina Yvonne Kathe Lindemann,
Egil Støre Blix,
Vilde Drageset Haakensen
:
ESMO-kongressen 2025 – dette ser de norske onkologene frem til
Alexios Matikas,
Bjørn Naume,
Hans Wildiers,
Gabe Sonke,
Maria Vittoria Dieci,
Andreas Karakatsanis
m.fl.:
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: A study protocol of ARIADNE
Ingrid Dyvik,
Gro Live Fagereng,
Tonje Lien,
Vigdis Nygaard,
Laxmi Silwal-Pandit,
J Christopher Noon
m.fl.:
Comprehensive genomic profiling of circulating tumor DNA for treatment recommendation: A sub-project of the IMPRESS-Norway trial.
2024 ARKIV
Åslaug Helland,
Eli Sihn Samdal Steinskog,
Egil Støre Blix,
Åsmund Flobak,
Sigmund Brabrand,
Katarina Puco
m.fl.:
Hever kvaliteten på behandling av kreft
Cecilie Fredvik Torkildsen,
Kristina Yvonne Kathe Lindemann,
Katharina Bischof,
Guro Aune,
Ingvild Vistad,
Vibeke Anett Ingebrigtsen
m.fl.:
456 Molecular characteristics of gynaecological cancer patients in the IMPRESS-Norway trial – a national prospective, non-randomized clinical trial evaluating the efficacy of anti-cancer drugs on new indications
Camilla Øvrebø ONDRČKOVA,
Åslaug Helland,
Egil Støre Blix,
Daniel Heinrich,
Kristina Yvonne Kathe Lindemann
:
ESMO-kongressen 2023 – dette gleder kreftlegene seg til
20. oktober 2023 ARKIV
Kjetil Tasken,
Hege Elisabeth Giercksky Russnes,
Eline Aas,
Line Bjørge,
Egil Støre Blix,
Terje C. Ahlquist
m.fl.:
A national precision cancer medicine implementation initiative for Norway
Åslaug Helland,
Hege Elisabeth Giercksky Russnes,
Gro Live Fagereng,
Khalid Ibrahim Al-Shibli,
Yvonne Andersson,
Thomas Berg
m.fl.:
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway (Journal of Translational Medicine, (2022), 20, 1, (225), 10.1186/s12967-022-03432-5)
Egil Støre Blix
:
A national precision cancer medicine implementation initiative for Norway
Egil Støre Blix
:
Åslaug Helland og Egil Blix, • IMPRESS–Norway - hvordan går det?
2022 ARKIV
Åslaug Helland,
Hege Elisabeth Giercksky Russnes,
Gro Live Fagereng,
Khalid Ibrahim Al-Shibli,
Yvonne Andersson,
Thomas Berg
m.fl.:
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
Egil Støre Blix
:
Persontilpasset medisin hos pasienter med brystkreft
2019 ARKIV
Hans Petter Eikesdal,
Synnøve Yndestad,
Egil Støre Blix,
Steinar Lundgren,
Geirfinn Vagstad,
Helge Espelid
m.fl.:
Neoadjuvant olaparib monotherapy in primary triple negative breast cancer
2019 ARKIV
Hans Petter Eikesdal,
Christina Clausen,
Egil Støre Blix,
Steinar Lundgren,
Geirfinn Vagstad,
Helge Espelid
m.fl.:
Neoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer
2019 ARKIV
Mona Stedenfeldt,
Pål Øian,
Mika Gissler,
Egil Støre Blix,
Jouko Pirhonen
:
Authors' reply: Risk factors for obstetric anal sphincter injury after a successful multicentre interventional programme
Kari Flo,
Anne Husebekk,
Åse VÅrtun,
Egil Støre Blix,
Tom Wilsgaard,
Ganesh Acharya
:
A longitudinal study of maternal vascular reactivity, circulating endothelial progenitor celss and inflammatory response during the second half of pregnancy
Pregnancy Hypertension 2013 ARKIV
De 50 siste resultatene vises på siden. Se alle arbeider i NVA her →